
GERMANY - Heidelberg Innovation and BioMed Venture exit BioVision
Venture capital groups Heidelberg Innovation and BioMed Venture have exited their stakes in BioVision GmbH to US-based molecular spectroscopy systems specialist Digilab LLC. Heidelberg Innovation and BioMed Venture, alongside other investors provided EUR 15m of expansion financing to the Hannover-based peptide profiling specialist in 2002. Since then the company has developed relationships with leading life science companies to facilitate their peptide biomarker diagnostic and therapeutic discovery needs. This is Heidelberg Innovation's second exit this year, following the sale of Microcuff GmbH to Kimberly Clarke Corporation in February.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater